These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

366 related articles for article (PubMed ID: 24222095)

  • 41. Lipoprotein ratios: Physiological significance and clinical usefulness in cardiovascular prevention.
    Millán J; Pintó X; Muñoz A; Zúñiga M; Rubiés-Prat J; Pallardo LF; Masana L; Mangas A; Hernández-Mijares A; González-Santos P; Ascaso JF; Pedro-Botet J
    Vasc Health Risk Manag; 2009; 5():757-65. PubMed ID: 19774217
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Pathogenesis and management of the dyslipidemia of the metabolic syndrome.
    Raal FJ
    Metab Syndr Relat Disord; 2009 Apr; 7(2):83-8. PubMed ID: 19400742
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Molecular sources of residual cardiovascular risk, clinical signals, and innovative solutions: relationship with subclinical disease, undertreatment, and poor adherence: implications of new evidence upon optimizing cardiovascular patient outcomes.
    Kones R
    Vasc Health Risk Manag; 2013; 9():617-70. PubMed ID: 24174878
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Sex differences in the impact of nonalcoholic fatty liver disease on cardiovascular risk factors.
    Du T; Sun X; Yuan G; Zhou X; Lu H; Lin X; Yu X
    Nutr Metab Cardiovasc Dis; 2017 Jan; 27(1):63-69. PubMed ID: 27956025
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Menopausal hormone therapy in women with dyslipidemia and nonalcoholic fatty liver disease.
    Polyzos SA; Lambrinoudaki I; Goulis DG
    Hormones (Athens); 2022 Sep; 21(3):375-381. PubMed ID: 35532850
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Dietary fatty acids and lipoprotein metabolism: new insights and updates.
    Ooi EM; Ng TW; Watts GF; Barrett PH
    Curr Opin Lipidol; 2013 Jun; 24(3):192-7. PubMed ID: 23619368
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Pitavastatin in cardiometabolic disease: therapeutic profile.
    Masana L
    Cardiovasc Diabetol; 2013; 12 Suppl 1(Suppl 1):S2. PubMed ID: 23819752
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Disturbed lipids, lipoproteins and triglyceride-rich lipoproteins as well as fasting and nonfasting non-high-density lipoprotein cholesterol in post-renal transplant patients.
    Kimak E; Ksiazek A; Baranowicz-Gaszczyk I; Solski J
    Ren Fail; 2007; 29(6):705-12. PubMed ID: 17763166
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Association of serum triglyceride-to-HDL cholesterol ratio with carotid artery intima-media thickness, insulin resistance and nonalcoholic fatty liver disease in children and adolescents.
    Pacifico L; Bonci E; Andreoli G; Romaggioli S; Di Miscio R; Lombardo CV; Chiesa C
    Nutr Metab Cardiovasc Dis; 2014 Jul; 24(7):737-43. PubMed ID: 24656140
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Usefulness of atherogenic dyslipidemia for predicting cardiovascular risk in patients with angiographically defined coronary artery disease.
    Arca M; Montali A; Valiante S; Campagna F; Pigna G; Paoletti V; Antonini R; Barillà F; Tanzilli G; Vestri A; Gaudio C
    Am J Cardiol; 2007 Nov; 100(10):1511-6. PubMed ID: 17996510
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Low- and high-density lipoprotein subclasses in subjects with nonalcoholic fatty liver disease.
    Sonmez A; Nikolic D; Dogru T; Ercin CN; Genc H; Cesur M; Tapan S; Karslioğlu Y; Montalto G; Banach M; Toth PP; Bagci S; Rizzo M
    J Clin Lipidol; 2015; 9(4):576-82. PubMed ID: 26228676
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Elevated triglycerides and low high-density lipoprotein cholesterol level as marker of very high risk in type 2 diabetes.
    Hermans MP; Valensi P
    Curr Opin Endocrinol Diabetes Obes; 2018 Apr; 25(2):118-129. PubMed ID: 29493554
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Mitochondrial Lipid Homeostasis at the Crossroads of Liver and Heart Diseases.
    Dabravolski SA; Bezsonov EE; Baig MS; Popkova TV; Orekhov AN
    Int J Mol Sci; 2021 Jun; 22(13):. PubMed ID: 34203309
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Does nonalcoholic fatty liver disease cause cardiovascular disease? Current knowledge and gaps.
    Santos RD; Valenti L; Romeo S
    Atherosclerosis; 2019 Mar; 282():110-120. PubMed ID: 30731283
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Non-HDL cholesterol and LDL cholesterol in the dyslipidemic classification in patients with nonalcoholic fatty liver disease.
    Du T; Sun X; Yu X
    Lipids Health Dis; 2017 Dec; 16(1):229. PubMed ID: 29197406
    [TBL] [Abstract][Full Text] [Related]  

  • 56. [Hypolipidemic therapy in patients with non-alcoholic fatty liver disease].
    Zvenigorodskaia LA; Samsonova NG; Mel'nikova NV; Cherkashova EA
    Eksp Klin Gastroenterol; 2010; (7):25-33. PubMed ID: 21033080
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Overproduction of very low-density lipoproteins is the hallmark of the dyslipidemia in the metabolic syndrome.
    Adiels M; Olofsson SO; Taskinen MR; Borén J
    Arterioscler Thromb Vasc Biol; 2008 Jul; 28(7):1225-36. PubMed ID: 18565848
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Catabolism of lipoproteins and metabolic syndrome.
    Therond P
    Curr Opin Clin Nutr Metab Care; 2009 Jul; 12(4):366-71. PubMed ID: 19474714
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Mechanisms of diabetic dyslipidemia: relevance for atherogenesis.
    Arca M; Pigna G; Favoccia C
    Curr Vasc Pharmacol; 2012 Nov; 10(6):684-6. PubMed ID: 23259553
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Irisin in patients with nonalcoholic fatty liver disease.
    Polyzos SA; Kountouras J; Anastasilakis AD; Geladari EV; Mantzoros CS
    Metabolism; 2014 Feb; 63(2):207-17. PubMed ID: 24140091
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.